VolitionRX (VNRX) Announces Earnings Results

VolitionRX (NYSEAMERICAN:VNRX) released its quarterly earnings results on Wednesday. The medical research company reported ($0.14) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.14), Fidelity Earnings reports.

VNRX stock traded down $0.07 during midday trading on Thursday, reaching $2.68. The company had a trading volume of 500 shares, compared to its average volume of 109,215. VolitionRX has a 1 year low of $1.44 and a 1 year high of $4.00.

In related news, Director Guy Archibald Innes purchased 50,000 shares of the business’s stock in a transaction on Thursday, August 16th. The stock was acquired at an average price of $2.00 per share, with a total value of $100,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

ILLEGAL ACTIVITY WARNING: “VolitionRX (VNRX) Announces Earnings Results” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2018/11/08/volitionrx-vnrx-announces-earnings-results.html.

About VolitionRX

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Further Reading: Earnings Per Share

Earnings History for VolitionRX (NYSEAMERICAN:VNRX)

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit